Astellas Plots US Portfolio Expansion
Executive Summary
US president Mark Reisenauer talked to Scrip about the company's next growth drivers, including fezolinetant for vasomotor symptoms and zolbetuximab for gastric cancer.
You may also be interested in...
Astellas Misses Again On Xospata Label Expansion Effort
A Phase III disappointment in a maintenance therapy setting for FLT3-mutated acute myeloid leukemia is yet another failed attempt by Astellas to add to Xospata’s label since US FDA approval in 2018.
Astellas CEO Yasukawa On Gene Therapy Challenges, Deal Strategies
Despite facing two clinical holds for its gene therapy candidates, Astellas is committed to proceeding with R&D projects in this modality. Outgoing CEO Kenji Yasukawa says technical challenges have motivated the firm's recent deals with academia and bioventures, and also provided updates on other key pipeline assets in the second part of this exclusive interview with Scrip.
2023 Will Be A Year Of Partnerships And Acquisitions For Astellas
Astellas’ Mike Luther sees 2023 as a year of growing assets and creating partnerships. The global head of search and evaluation business development told In Vivo about the company's focus on gene and cell therapy and what he thinks makes for a successful business deal.